Byetta does not raise pancreatitis risk, according to claims data
Analysis of a UnitedHealth Group transaction database found the risk of acute pancreatitis among incretin-based diabetes therapies - Amylin/Lilly's Byetta (exenatide) and Merck's Januvia (sitagliptin) - to be similar to that associated with metformin and glyburide, both agents with established safety profiles. The study, which was sponsored by Amylin and published in Current Medical Research and Opinion March 12, concluded that more comprehensive pharmaco-epidemiology studies are needed to more fully assess the risk. A safety alert from FDA in August 2008 regarding two fatal cases of pancreatitis in Byetta patients sparked a decline in sales, although analysts suggested that nausea associated with initiation of Byetta treatment may be the bigger impediment (1"The Pink Sheet," Feb. 2, 2009, p. 33)
You may also be interested in...
Pharmaceutical benefits manager's review of almost 800,000 claims does not show higher risk for these two drugs, despite label warnings.
Sponsors of GLP-1 diabetes therapies and their investors are eagerly awaiting spring for greater clarity about the prospects of the antidiabetic class
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.